

Marc R Radke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7652159/publications.pdf>

Version: 2024-02-01

12
papers

581
citations

1163117

8
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

977
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	15
2	Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. <i>Gynecologic Oncology</i> , 2021, 160, 786-792.	1.4	17
3	Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006083.	1.2	5
4	DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2021, 50, e50-e52.	1.1	1
5	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.	3.1	20
6	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	7.0	22
7	Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 407-414.	1.4	10
8	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
9	Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer. <i>Cancer Research</i> , 2020, 80, 857-867.	0.9	33
10	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. <i>Nature Communications</i> , 2019, 10, 5661.	12.8	45
11	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	9.4	278
12	Molecular phylogenetics and species-level systematics of <i>Baylisascaris</i> . <i>International Journal for Parasitology: Parasites and Wildlife</i> , 2018, 7, 450-462.	1.5	8